CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs
BOSTON and TOKYO, July 28, 2026 /PRNewswire/ -- CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to...
BOSTON and TOKYO, July 28, 2026 /PRNewswire/ -- CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.